{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["101(44)"],"submitter":["Obinata D"],"pubmed_abstract":["We performed a retrospective study to clarify the characteristics of prostate biopsies in patients treated with dutasteride, a benign prostate hyperplasia treatment drug that inhibits 5α-reductase. We studied the digital clinical data of 677 patients, including 96 cases treated with dutasteride, with suspected localized prostate cancer. All patients underwent transrectal ultrasonography-guided prostate biopsy between 2014 and 2017 in our department. A propensity score matching analysis was performed based on prostate-specific antigen (PSA) (calculated as double the PSA value for the dutasteride group) and age. Ninety-six patients in each of the dutasteride and control groups were assessed and their characteristics were compared. The characteristics of the patients in the dutasteride and co"],"journal":["Medicine"],"pagination":["e31658"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9646501"],"repository":["biostudies-literature"],"pubmed_title":["Characteristics of prostate biopsy in patients under the dutasteride treatment."],"pmcid":["PMC9646501"],"pubmed_authors":["Nakahara K","Takahashi S","Mochida J","Obinata D","Yoshizawa T","Yamaguchi K"],"additional_accession":[]},"is_claimable":false,"name":"Characteristics of prostate biopsy in patients under the dutasteride treatment.","description":"We performed a retrospective study to clarify the characteristics of prostate biopsies in patients treated with dutasteride, a benign prostate hyperplasia treatment drug that inhibits 5α-reductase. We studied the digital clinical data of 677 patients, including 96 cases treated with dutasteride, with suspected localized prostate cancer. All patients underwent transrectal ultrasonography-guided prostate biopsy between 2014 and 2017 in our department. A propensity score matching analysis was performed based on prostate-specific antigen (PSA) (calculated as double the PSA value for the dutasteride group) and age. Ninety-six patients in each of the dutasteride and control groups were assessed and their characteristics were compared. The characteristics of the patients in the dutasteride and co","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-05T12:31:59.136Z","creation":"2025-04-05T12:31:59.136Z"},"accession":"S-EPMC9646501","cross_references":{"pubmed":["36343082"],"doi":["10.1097/MD.0000000000031658"]}}